Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here. Yesterday’s Nobel wins for Katalin Karikó and Drew Weissman called to mind the humble beginnings of mRNA research — and the fact that Karikó’s scientific career nearly ended before their key discovery, as she explained back in 2020.
The need-to-know this morning
• Eli Lilly said it would acquire Point Biopharma in an all-cash deal valued at $1.4 billion.
• Sanofi is paying $175 million to license Johnson & Johnson’s late-stage vaccine for E. coli.
• Regeneron Pharmaceuticals expanded its partnership with Intellia Therapeutics to develop two more CRISPR-based medicines.
• ALX Oncology said its experimental immunotherapy improved the number of tumors that responded, or shrank, when added to other cancer medicines in gastric cancer. The drug targets CD47, an immune checkpoint. Shares of the company rose 105% in premarket trading.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.